Jack M. Qian

Jack M. Qian

Auto-generated profile, based on publicly available information

Jack M. Qian

Department of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2016 in Cancer
Verified
Journal Article
Open access
PDF file
JQJack M. Qian
Jack M. Qian
JYJames B. Yu
James B. Yu
HKHarriet M. Kluger
Harriet M. Kluger
VCVeronica Chiang
Veronica Chiang
BACKGROUND: Growing evidence suggests that immunotherapy and radiation therapy can be synergistic in the treatment of cancer. This study was performed to determine the effect of the relative timing and type of immune checkpoint therapy on the response of melanoma brain metastases (BrMets) to treatment with stereotactic radiosurgery (SRS).METHODS: Seventy‐five melanoma patients with 566 BrMets were treated with both SRS and immune checkpoint therapy between 2007 and 2015 at a single institution. Immunotherapy and radiosurgery treatment of any single lesion were considered concurrent if SRS was administered within 4 weeks of immunotherapy. The impact of the timing and type of immunotherapy on the lesional response was determined with the Wilcoxon rank‐sum test, which was used to compare the median percent lesion volume change 1.5, 3, and 6 months after SRS treatment, with significance determined by P = .0167 according to the Bonferroni correction for multiple comparisons.RESULTS: Concurrent use of immunotherapy and SRS resulted in a significantly greater median percent reduction in the lesion volume at 1.5 (−63.1% vs −43.2%, P < .0001), 3 (−83.0% vs −52.8%, P < .0001), and 6 months (−94.9% vs −66.2%, P < .0001) in comparison with nonconcurrent therapy. The median percent reduction in the lesion volume was also significantly greater for anti–programmed cell death protein 1 (anti–PD‐1) than anti–cytotoxic T‐lymphocyte‐associated protein 4 (anti–CTLA‐4) at 1.5 (−71.1% vs −48.2%, P < .0001), 3 (−89.3% vs −66.2%, P < .0001), and 6 months (−95.1% vs −75.9%, P = .0004).CONCLUSIONS: The administration of immunotherapy within 4 weeks of SRS results in an improved lesional response of melanoma BrMets in comparison with treatment separated by longer than 4 weeks. Anti–PD‐1 therapy also results in a greater lesional response than anti–CTLA‐4 after SRS. Cancer 2016;122:3051‐3058. © 2016 American Cancer Society.

3 February 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
JQJack M. Qian
Jack M. Qian
JSJonathan D. Schoenfeld
Jonathan D. Schoenfeld
Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment over the past decade. However, although the immune landscape suggests a strong rationale for the use of these agents in patients with head and neck squamous cell carcinoma, the available clinical evidence indicates that most patients currently do not respond to ICI monotherapy. Radiotherapy is a primary treatment modality for many patients with locally advanced head and neck cancer. While ionizing radiation traditionally has been thought to act in a purely cytotoxic fashion, a growing body of preclinical studies have demonstrated additional profound immunomodulatory effects. Consequently, there has been a surge of interest in the potential synergy between radiotherapy and immunotherapy, both the potential for radiotherapy to augment the systemic anti-tumor immune response and the potential for immunotherapy to improve in-field tumor response to radiation. In this review, we summarize the current preclinical and clinical evidence for radioimmunotherapy, with a particular focus on studies directly relevant to head and neck squamous cell carcinoma, as well as existing challenges and future directions for this emerging field.

1 October 2017 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
YAYi An
Yi An
WJWen Jiang
Wen Jiang
BKBetty Y.S. Kim
Betty Y.S. Kim
JQJack M. Qian
Jack M. Qian
CTChad Tang
Chad Tang
JLJing Li
Jing Li

8 March 2017 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
JQJack M. Qian
Jack M. Qian
AMAmit Mahajan
Amit Mahajan
JYJames B. Yu
James B. Yu
ATA. John Tsiouris
A. John Tsiouris
SGSarah B. Goldberg
Sarah B. Goldberg
VCVeronica Chiang
Veronica Chiang

14 September 2020 in Cancer
Verified
Journal Article
Closed access
PDF file
JQJack M. Qian
Jack M. Qian
AMAllison M. Martin
Allison M. Martin
KMKate Martin
Kate Martin
LHLubna Hammoudeh
Lubna Hammoudeh
PCPaul J. Catalano
Paul J. Catalano
AAAyal A. Aizer
Ayal A. Aizer

20 September 2025 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
AAAyal A. Aizer
Ayal A. Aizer
STShyam K. Tanguturi
Shyam K. Tanguturi
DSDiana Shi
Diana Shi
PCPaul Catalano
Paul Catalano
KSKee-Young Shin
Kee-Young Shin
RRRifaquat Rahman
Rifaquat Rahman
PURPOSE: Stereotactic radiation (SRS/SRT) as opposed to whole-brain radiation (WBRT) represents the standard of care for patients with a limited number of brain metastases given the relatively favorable toxicity profile associated with stereotactic treatment. However, in patients with small cell lung cancer (SCLC), WBRT remains standard because of a lack of prospective data supporting SRS/SRT and concerns related to intracranial progression and neurologic death when WBRT is omitted. We conducted a single-arm, multicenter, phase II trial of SRS/SRT in patients with SCLC and 1-10 brain metastases to assess neurologic death rates relative to historical controls managed with WBRT (ClinicalTrials.gov identifier: NCT03391362 ). METHODS: Patients were eligible if they had SCLC or an extrathoracic small cell primary and 1-10 brain metastases. Previous brain-directed radiation including prophylactic cranial irradiation was not permitted. Neurologic death was defined as marked, progressive, radiographic brain progression accompanied by corresponding neurologic symptomatology without systemic disease progression or systemic symptoms of a life-threatening nature. Close imaging-based surveillance of the brain post-SRS/SRT was used. RESULTS: Between February 2018 and April 2023, 100 patients were enrolled. The median number of brain metastases was 2 (IQR, 1-4; range, 1-10). The median overall survival was 10.2 months; only 22% of patients required salvage WBRT. In total, 20 neurologic deaths were observed, relative to 64 non-neurologic deaths. The neurologic death rate at 1 year was 11.0% (95% CI, 5.8 to 18.1); the historical rate in patients managed with WBRT was 17.5%. CONCLUSION: Our prospective, multi-institutional study demonstrated low rates of neurologic death when SRS/SRT as opposed to WBRT is used in patients with SCLC and 1-10 brain metastases who are surveilled closely post-treatment, supporting the utility of stereotactic approaches in this population.